Literature DB >> 34791070

Liver transplant outcomes after ex vivo machine perfusion: a meta-analysis.

Belle Liew1, David Nasralla1,2, Satheesh Iype1,2, Joerg-Matthias Pollok1,2, Brian Davidson1,2, Dimitri A Raptis1,2.   

Abstract

BACKGROUND: The pressure on liver-transplant programmes has expanded the usage of extended-criteria allografts. Machine perfusion may be better than conventional static cold storage (SCS) in alleviating ischaemia-reperfusion injury in this setting. Recipient outcomes with hypothermic or normothermic machine perfusion were assessed against SCS here.
METHODS: A search in MEDLINE, EMBASE and Scopus was conducted in February 2021. Primary studies investigating ex vivo machine perfusion were assessed for the following outcomes: morbidity, ICU and hospital stay, graft and patient survival rates and relative costs. Meta-analysis was performed to obtain pooled summary measures.
RESULTS: Thirty-four articles involving 1742 patients were included, of which 20 were used for quantitative synthesis. Odds ratios favoured hypothermic machine perfusion (over SCS) with less early allograft dysfunction, ischaemic cholangiopathy, non-anastomotic strictures and graft loss. Hypothermic machine perfusion was associated with a shorter hospital stay and normothermic machine perfusion with reduced graft injury. Two randomized clinical trials found normothermic machine perfusion reduced major complication risks.
CONCLUSION: Machine perfusion assists some outcomes with potential cost savings.
© The Author(s) 2021. Published by Oxford University Press on behalf of BJS Society Ltd. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Year:  2021        PMID: 34791070     DOI: 10.1093/bjs/znab364

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  1 in total

Review 1.  Hospital-Based Health Technology Assessment of Machine Perfusion Systems for Human Liver Transplantation.

Authors:  Paolo De Simone; Davide Ghinolfi
Journal:  Transpl Int       Date:  2022-05-27       Impact factor: 3.842

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.